Can absolute neutrophil count (ANC) be elevated in Chronic Myeloid Leukemia (CML)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 1, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Absolute Neutrophil Count in Chronic Myeloid Leukemia

Yes, the absolute neutrophil count (ANC) can be significantly elevated in Chronic Myeloid Leukemia (CML), and is often one of the hallmark laboratory findings of the disease. CML is characterized by uncontrolled proliferation of myeloid cells, particularly neutrophils and their precursors, leading to markedly increased white blood cell counts.

Neutrophil Patterns in CML

Typical Presentation

  • Leukocytosis with elevated absolute neutrophil count is the classic presentation of CML
  • White blood cell counts typically range from mildly elevated to extremely high (>100,000/μL)
  • The peripheral blood shows a full spectrum of myeloid cells at various stages of maturation
  • Basophilia is a characteristic finding, with absolute basophil counts ≥200/mm³ in most cases 1

Atypical Presentations

  • Some patients may present with "pre-leukemic CML" with normal or only mildly elevated WBC (3,600-14,300/μL) 2
  • Rarely, CML can present with isolated thrombocytosis without significant leukocytosis 3
  • In these atypical cases, the diagnosis relies on cytogenetic or molecular detection of t(9;22) or BCR-ABL1 fusion gene

Diagnostic Clues

Key Laboratory Findings

  • Elevated absolute neutrophil count with a left shift (presence of immature granulocytes)
  • Absolute basophilia (≥0.43 × 10⁹/L) has high sensitivity and specificity for CML screening 1
  • Elevated immature granulocyte count (≥0.46 × 10⁹/L) is another valuable screening parameter 1
  • Low or absent neutrophil alkaline phosphatase (NAP) score (unlike in leukemoid reactions)

Distinguishing Features

  • In CML, neutrophils may appear functionally normal or even hyperactive 4
  • The presence of small, hypolobated megakaryocytes in bone marrow is characteristic of CML 2
  • Increased microvascular density with tortuous, abnormally branching vessels in bone marrow 2

Clinical Significance

Disease Monitoring

  • ANC is monitored during treatment as part of response assessment
  • Complete hematologic remission requires normalization of blood counts, including ANC ≥1.0×10⁹/L 5
  • Persistent neutrophilia despite treatment may indicate treatment failure or disease progression

Treatment Considerations

  • Cytoreductive therapy is often needed to control excessive neutrophilia
  • Tyrosine kinase inhibitors (TKIs) are the mainstay of treatment and typically normalize neutrophil counts
  • Monitoring for neutropenia is important during TKI therapy, as it can be a common side effect

Differential Diagnosis

When encountering elevated neutrophil counts, consider:

  • Leukemoid reactions (infection, inflammation)
  • Chronic neutrophilic leukemia
  • Other myeloproliferative neoplasms
  • Chronic myelomonocytic leukemia (CMML) - which can present with WBC ≥13 × 10⁹/L in the myeloproliferative variant 6

Pitfalls and Caveats

  • Relying solely on ANC or WBC for diagnosis is insufficient; cytogenetic or molecular confirmation of BCR-ABL1 is essential
  • Some CML cases may present with normal WBC counts or even isolated thrombocytosis
  • Basophilia is a more specific marker for CML than neutrophilia alone
  • Sequential monitoring of blood counts is important, as CML may evolve from subtle abnormalities to more obvious ones over time

Remember that while elevated ANC is common in CML, the definitive diagnosis requires demonstration of the Philadelphia chromosome or BCR-ABL1 fusion gene.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.